Biomarkers of Aortopathy in Marfan Syndrome

Research output: Contribution to journalArticle

Abstract

Marfan Syndrome (MFS) is an autosomal dominant, genetically inherited connective tissue disorder which primarily affects the cardiovascular system, but can also have systemic manifestations. First described in 1896, MFS has a prevalence of around 1/5000 in the general population. It is becoming increasingly common to see patients with MFS in a clinical setting due to the improved care of patients with adult congenital heart disease and general improvement in survival. Mortality, however, remains high largely due to the risk of aortic dissection as a result of the aortic root dilatation frequently seen in these patients. Contemporary management has therefore been focused on imaging-based surveillance to prevent these catastrophic events and intervene surgically in a timely manner. However, it is increasingly recognized that some patients do suffer aortic dissection below the expected threshold for surgical intervention. With this in mind, there has been interest in the role of biomarkers as an adjunct to imaging in the care of these patients. This article will provide an overview of the literature on potential biomarkers studied so far in MFS, as well as potential future directions.

Original languageEnglish
Pages (from-to)92-97
Number of pages6
JournalCardiology in Review
Volume28
Issue number2
Early online date23 Jan 2020
DOIs
Publication statusE-pub ahead of print - 23 Jan 2020

Fingerprint

Marfan Syndrome
Biomarkers
Dissection
Patient Care
Cardiovascular System
Connective Tissue
Dilatation
Heart Diseases
Survival
Mortality
Population

Keywords

  • Marfan Syndrome
  • biomarkers
  • aortopathy
  • aortic dissection

Cite this

@article{36a0d57343b449a48861b6fd86f5032e,
title = "Biomarkers of Aortopathy in Marfan Syndrome",
abstract = "Marfan Syndrome (MFS) is an autosomal dominant, genetically inherited connective tissue disorder which primarily affects the cardiovascular system, but can also have systemic manifestations. First described in 1896, MFS has a prevalence of around 1/5000 in the general population. It is becoming increasingly common to see patients with MFS in a clinical setting due to the improved care of patients with adult congenital heart disease and general improvement in survival. Mortality, however, remains high largely due to the risk of aortic dissection as a result of the aortic root dilatation frequently seen in these patients. Contemporary management has therefore been focused on imaging-based surveillance to prevent these catastrophic events and intervene surgically in a timely manner. However, it is increasingly recognized that some patients do suffer aortic dissection below the expected threshold for surgical intervention. With this in mind, there has been interest in the role of biomarkers as an adjunct to imaging in the care of these patients. This article will provide an overview of the literature on potential biomarkers studied so far in MFS, as well as potential future directions.",
keywords = "Marfan Syndrome, biomarkers, aortopathy, aortic dissection",
author = "Zaid Iskandar and Ify Mordi and Chim Lang and Jeffrey Huang and Anna Choy",
year = "2020",
month = "1",
day = "23",
doi = "10.1097/CRD.0000000000000289",
language = "English",
volume = "28",
pages = "92--97",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott, Williams & Wilkins",
number = "2",

}

Biomarkers of Aortopathy in Marfan Syndrome. / Iskandar, Zaid; Mordi, Ify; Lang, Chim; Huang, Jeffrey; Choy, Anna.

In: Cardiology in Review, Vol. 28, No. 2, 01.03.2020, p. 92-97.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biomarkers of Aortopathy in Marfan Syndrome

AU - Iskandar, Zaid

AU - Mordi, Ify

AU - Lang, Chim

AU - Huang, Jeffrey

AU - Choy, Anna

PY - 2020/1/23

Y1 - 2020/1/23

N2 - Marfan Syndrome (MFS) is an autosomal dominant, genetically inherited connective tissue disorder which primarily affects the cardiovascular system, but can also have systemic manifestations. First described in 1896, MFS has a prevalence of around 1/5000 in the general population. It is becoming increasingly common to see patients with MFS in a clinical setting due to the improved care of patients with adult congenital heart disease and general improvement in survival. Mortality, however, remains high largely due to the risk of aortic dissection as a result of the aortic root dilatation frequently seen in these patients. Contemporary management has therefore been focused on imaging-based surveillance to prevent these catastrophic events and intervene surgically in a timely manner. However, it is increasingly recognized that some patients do suffer aortic dissection below the expected threshold for surgical intervention. With this in mind, there has been interest in the role of biomarkers as an adjunct to imaging in the care of these patients. This article will provide an overview of the literature on potential biomarkers studied so far in MFS, as well as potential future directions.

AB - Marfan Syndrome (MFS) is an autosomal dominant, genetically inherited connective tissue disorder which primarily affects the cardiovascular system, but can also have systemic manifestations. First described in 1896, MFS has a prevalence of around 1/5000 in the general population. It is becoming increasingly common to see patients with MFS in a clinical setting due to the improved care of patients with adult congenital heart disease and general improvement in survival. Mortality, however, remains high largely due to the risk of aortic dissection as a result of the aortic root dilatation frequently seen in these patients. Contemporary management has therefore been focused on imaging-based surveillance to prevent these catastrophic events and intervene surgically in a timely manner. However, it is increasingly recognized that some patients do suffer aortic dissection below the expected threshold for surgical intervention. With this in mind, there has been interest in the role of biomarkers as an adjunct to imaging in the care of these patients. This article will provide an overview of the literature on potential biomarkers studied so far in MFS, as well as potential future directions.

KW - Marfan Syndrome

KW - biomarkers

KW - aortopathy

KW - aortic dissection

UR - http://www.scopus.com/inward/record.url?scp=85079019440&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000289

DO - 10.1097/CRD.0000000000000289

M3 - Article

C2 - 31985522

VL - 28

SP - 92

EP - 97

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 2

ER -